In the News
powered by Ovast-
Melanoma Agent Surprise: Brain Tumors Shrink Too - Medscape
google.com 1 week, 1 day agoCancer Research UK Melanoma Agent Surprise: Brain Tumors Shrink Too Medscape May 17, 2012 , The efficacy of the investigational cancer agent dabrafenib (GlaxoSmithKline) evidently extends beyond its targets of solid tumors and melanomas that harbor BRAF mutations, according to a phase 1 trial. The agent also reduced the size of ... Dabrafenib shrinks melanoma brain metastases in phase I clinical trial Drug could boost brain cancer survival RPT-Glaxo melanoma drug combo shows promise in small trial -
-
FDA Panel Votes Against Pfizer Rare Disease Drug
yahoo.com 1 day, 18 hours ago(Reuters) - Pfizer Inc said a U.S. health advisory panel voted against its drug to treat a rare neurodegenerative disease as the data did not show enough evidence of efficacy. The panel's recommendation will be considered by the U.S. Food and ...

















Loading More Stories